Literature DB >> 25908301

Soluble epoxide hydrolase null mice exhibit female and male differences in regulation of vascular homeostasis.

Luca Vanella1, Martina Canestraro2, Craig R Lee3, Jian Cao4, Darryl C Zeldin3, Michal L Schwartzman2, Nader G Abraham5.   

Abstract

Increased CYP epoxygenase activity and consequently up regulation of epoxyeicosatrienoic acids (EETs) levels provides protection against metabolic syndrome and cardiovascular diseases. Conversion of arachidonic acid epoxides to diols by soluble epoxide hydrolase (sEH) diminishes the beneficial cardiovascular properties of these epoxyeicosanoids. We therefore examined the possible biochemical consequences of sEH deletion on vascular responses in male and female mice. Through the use of the sEH KO mouse, we provide evidence of differences in the compensatory response in the balance between nitric oxide (NO), carbon monoxide (CO), EETs and the vasoconstrictor 20-HETE in male and female KO mice. Serum levels of adiponectin, TNFα, IL-1b and MCP1 and protein expression in vascular tissue of p-AMPK, p-AKT and p-eNOS were measured. Deletion of sEH caused a significant (p<0.05) decrease in body weight, and an increase in adiponectin, pAMPK and pAKT levels in female KO mice compared to male KO mice. Gene deletion resulted in a higher production of renal EETs in female KO compared to male KO mice and, concomitantly, we observed an increase in renal 20-HETEs levels and superoxide anion production only in male KO mice. sEH deletion increased p-AKT and p-eNOS protein expression but decreased p-AMPK levels in female KO mice. Increased levels of p-eNOS at Thr-495 were observed only in KO male mice. While p-eNOS at 1177 were not significantly different between male and female. Nitric oxide production was unaltered in male KO mice. These results provide evidence of gender differences in the preservation of vascular homeostasis in response to sEH deletion which involves regulation of phosphorylation of eNOS at the 495 site.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adiponectin; EETs; pAKT; pAMPK

Mesh:

Substances:

Year:  2015        PMID: 25908301      PMCID: PMC4575626          DOI: 10.1016/j.prostaglandins.2015.04.004

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  65 in total

1.  Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Authors:  Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

Review 2.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

3.  CYP4A2-induced hypertension is 20-hydroxyeicosatetraenoic acid- and angiotensin II-dependent.

Authors:  Komal Sodhi; Cheng-Chia Wu; Jennifer Cheng; Katherine Gotlinger; Kazuyoshi Inoue; Mohan Goli; John R Falck; Nader G Abraham; Michal L Schwartzman
Journal:  Hypertension       Date:  2010-09-13       Impact factor: 10.190

Review 4.  20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension.

Authors:  Jan M Williams; Sydney Murphy; Marilyn Burke; Richard J Roman
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

5.  Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.

Authors:  Ketul R Chaudhary; Mohamed Abukhashim; Sung Hee Hwang; Bruce D Hammock; John M Seubert
Journal:  J Cardiovasc Pharmacol       Date:  2010-01       Impact factor: 3.105

6.  Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension.

Authors:  Arzu Ulu; Todd R Harris; Christophe Morisseau; Christina Miyabe; Hiromi Inoue; Gertrud Schuster; Hua Dong; Ana-Maria Iosif; Jun-Yan Liu; Robert H Weiss; Nipavan Chiamvimonvat; John D Imig; Bruce D Hammock
Journal:  J Cardiovasc Pharmacol       Date:  2013-09       Impact factor: 3.105

7.  Renoprotective effects of nitric oxide in angiotensin II-induced hypertension in the rat.

Authors:  S Y Chin; C T Wang; D S Majid; L G Navar
Journal:  Am J Physiol       Date:  1998-05

8.  Endothelial-specific CYP4A2 overexpression leads to renal injury and hypertension via increased production of 20-HETE.

Authors:  Kazuyoshi Inoue; Komal Sodhi; Nitin Puri; Katherine H Gotlinger; Jiang Cao; Rita Rezzani; John R Falck; Nader G Abraham; Michal Laniado-Schwartzman
Journal:  Am J Physiol Renal Physiol       Date:  2009-08-12

9.  20-hydroxyeicosatetraenoic acid is an endothelium-dependent vasoconstrictor in rabbit arteries.

Authors:  B Escalante; K Omata; W Sessa; S G Lee; J R Falck; M L Schwartzman
Journal:  Eur J Pharmacol       Date:  1993-04-22       Impact factor: 4.432

10.  Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.

Authors:  Ahmed A Elmarakby; Jessica Faulkner; Chelsey Pye; Katelyn Rouch; Abdulmohsin Alhashim; Krishna Rao Maddipati; Babak Baban
Journal:  Clin Sci (Lond)       Date:  2013-10       Impact factor: 6.124

View more
  9 in total

1.  Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption.

Authors:  M H Napimoga; E P Rocha; C A Trindade-da-Silva; A P D Demasi; E F Martinez; C G Macedo; H B Abdalla; A Bettaieb; F G Haj; J T Clemente-Napimoga; B Inceoglu; B D Hammock
Journal:  J Periodontal Res       Date:  2018-05-31       Impact factor: 4.419

Review 2.  Metabolic/inflammatory/vascular comorbidity in psychiatric disorders; soluble epoxide hydrolase (sEH) as a possible new target.

Authors:  W Swardfager; M Hennebelle; D Yu; B D Hammock; A J Levitt; K Hashimoto; A Y Taha
Journal:  Neurosci Biobehav Rev       Date:  2018-02-02       Impact factor: 8.989

3.  Ablation of soluble epoxide hydrolase reprogram white fat to beige-like fat through an increase in mitochondrial integrity, HO-1-adiponectin in vitro and in vivo.

Authors:  Lu Liu; Nitin Puri; Marco Raffaele; Joseph Schragenheim; Shailendra P Singh; J Alyce Bradbury; Lars Bellner; Luca Vanella; Darryl C Zeldin; Jian Cao; Nader G Abraham
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-07-21       Impact factor: 3.072

4.  Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice.

Authors:  Ye Zhu; Maximilian Blum; Uwe Hoff; Tim Wesser; Mandy Fechner; Christina Westphal; Dennis Gürgen; Rusan Ali Catar; Aurelie Philippe; Kaiyin Wu; Gordana Bubalo; Michael Rothe; Steven M Weldon; Duska Dragun; Wolf-Hagen Schunck
Journal:  PLoS One       Date:  2016-01-04       Impact factor: 3.240

Review 5.  Targeting arachidonic acid-related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles.

Authors:  Sherif M Shoieb; Mahmoud A El-Ghiaty; Ayman O S El-Kadi
Journal:  Emergent Mater       Date:  2020-11-17

6.  Deletion of NoxO1 limits atherosclerosis development in female mice.

Authors:  Giulia K Buchmann; Christoph Schürmann; Tim Warwick; Marcel H Schulz; Manuela Spaeth; Oliver J Müller; Katrin Schröder; Hanjoong Jo; Norbert Weissmann; Ralf P Brandes
Journal:  Redox Biol       Date:  2020-09-04       Impact factor: 11.799

7.  Soluble Epoxide Hydrolase Deletion Limits High-Fat Diet-Induced Inflammation.

Authors:  Karen M Wagner; Jun Yang; Christophe Morisseau; Bruce D Hammock
Journal:  Front Pharmacol       Date:  2021-12-17       Impact factor: 5.810

8.  Sex-Specific Differences in Resolution of Airway Inflammation in Fat-1 Transgenic Mice Following Repetitive Agricultural Dust Exposure.

Authors:  Arzu Ulu; Jalene V Velazquez; Abigail Burr; Stefanie N Sveiven; Jun Yang; Carissa Bravo; Bruce D Hammock; Tara M Nordgren
Journal:  Front Pharmacol       Date:  2022-01-13       Impact factor: 5.810

9.  A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction.

Authors:  Takahiro Kitsuka; Aya Shiraki; Jun-Ichi Oyama; Hironori Nakagami; Atsushi Tanaka; Koichi Node
Journal:  Sci Rep       Date:  2022-04-28       Impact factor: 4.996

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.